(Q44808739)

6 December 2017

Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy (English)

1 reference

6 December 2017

0 references

1 reference

1 reference

1 reference

1 reference

N Cézé

1

1 reference

6 December 2017

G Thibault

2

1 reference

6 December 2017

G Goujon

3

1 reference

6 December 2017

J Viguier

4

1 reference

6 December 2017

H Watier

5

1 reference

6 December 2017

E Dorval

6

1 reference

6 December 2017

T Lecomte

7

1 reference

6 December 2017

30 March 2011

1 reference

Cancer Chemotherapy and Pharmacology

6 December 2017

1 reference

6 December 2017

68

1 reference

6 December 2017

5

1 reference

6 December 2017

1305-1313

1 reference

https://scigraph.springernature.com/pub.10.1007/s00280-011-1610-3

6 December 2017

0 references

cites work

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1610-3

Systemic therapy for colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1610-3

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1610-3

Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1610-3

Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1610-3

Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1610-3

Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1610-3

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1610-3

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1610-3

Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1610-3

Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1610-3

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1610-3

Effector memory T cells, early metastasis, and survival in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1610-3

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1610-3

Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1610-3

Five-year cancer cure: relation to total amount of peripheral lymphocytes and neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1610-3

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1610-3

Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1610-3

Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1610-3

Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1610-3

Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1610-3

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1610-3

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1610-3

Biological indices predictive of survival in 519 Italian terminally ill cancer patients. Italian Multicenter Study Group on Palliative Care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1610-3

Selecting and maintaining a diverse T-cell repertoire

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1610-3

CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1610-3

Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1610-3

Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1610-3

Is there a difference in survival between right- versus left-sided colon cancers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1610-3

IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1610-3

10.1007/S00280-011-1610-3

21 January 2018

Identifiers

DOI

1 reference

6 December 2017

1 reference